SCHEMBL426819

SCHEMBL426819

Cc1ccc(C(C)(OCCN2CCCCC2)C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
ALDH1A1 P00352 2/20 0.53
HRH3 Q9Y5N1 6/20 0.49
CHRM2 P08172 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
CHRM1 P11229 1/20 0.49
DRD1 P21728 1/20 0.49
TBXA2R P21731 1/20 0.49
ACHE P22303 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A4 P31645 1/20 0.49
ADRA1A P35348 1/20 0.49
OPRM1 P35372 1/20 0.49
DRD3 P35462 1/20 0.49
SLC6A3 Q01959 1/20 0.49
KCNH2 Q12809 1/20 0.49
PSMB1 P20618 2/20 0.49
PSMB5 P28074 2/20 0.49
PSMB2 P49721 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL429374 0.88 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1HRH3CHRM2HTR1A
SCHEMBL464533 0.84 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1HRH3CHRM2HTR1A
SCHEMBL28321587 0.71 MEN1 (0.48) SMN1; SMN2ALDH1A1HRH3CHRM2DRD3
SCHEMBL447615 0.70 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1HRH3CHRM2HTR1A
SCHEMBL11300332 0.70 NPSR1 (0.51) SMN1; SMN2ALDH1A1HRH3CHRM2HTR1A
SCHEMBL82435 0.69 HRH3 (0.73) HRH3PSMB1PSMB5PSMB2KDM4E
SCHEMBL8353927 0.69 MEN1 (0.57) HRH3KDM4EMEN1KMT2AHRH1
SCHEMBL26532168 0.69 TSHR (0.39) ALDH1A1ACHESLC6A4KCNH2KDM4E
SCHEMBL12035585 0.69 HRH3 (0.73) HRH3PSMB1PSMB5PSMB2KDM4E
SCHEMBL30617893 0.69 CHRM2 (0.84) SMN1; SMN2ALDH1A1HRH3CHRM2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642624-B2 Substituted alkylamine derivatives and methods of use AMGEN INC. (US) 2014-02-04 US disclosed
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065185-A1 SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE AADAC, NAT1, PIGO SMN1; SMN2 1829/4885ALDH1A1 327/4885HRH3 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.